PAVMNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
PAVmed Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$2.25−0.16 (-6.64%)
Close on Oct 19, 2026
- Market cap
- $14.11M
- P/E (TTM)
- –
- Dividend yield
- –
PAVmed Inc. revenue by segment
By business segment
By product or service
| Revenue | Q3 23 | Q2 23 | Q1 23 | Q4 22 | Q3 22 | Q2 22 | Q1 22 | Q4 21 | Q3 21 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Royalty [Member] | – | – | – | – | – | – | $100.00M | $99.00M | – | – | – |
| Minimum Annual Royalty Fee [Member] | – | – | – | – | – | – | $100.00M | – | – | – | – |
| EsoGuard Test [Member] | – | – | $446.00K | – | – | – | – | – | – | – | – |
By region
From the segment and revenue-disaggregation notes of PAVmed's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.